
1. monaldi arch chest dis. 2012 mar;77(1):29-31.

sarcoidosis multiple sclerosis: systemic toxicity associated use 
interferon-beta therapy.

carbonelli c(1), montepietra s, caruso a, cavazza a, feo c, menzella f, motti l, 
zucchi l.

author information: 
(1)pulmonology unit, department cardiology, thoracic vascular surgery 
critical care medicine, azienda ospedaliera asmn, istituto di ricovero e cura a
carattere scientifico, reggio emilia, italy. cristiano.carbonelli@asmn.re.it

sarcoidosis multi-systemic inflammatory disease unknown origin
characterized presence noncaseating epitheloid cell granulomas in
multiple organs. diagnosis made basis compatible
clinical-radiological scenario histological demonstration typical 
granulomas affected tissues. interferons immuno-modulators have
been used wide range diseases, including hepatitis c virus infection,
multiple sclerosis, multiple myeloma types tumours, including
leukemia, lymphomas, kaposi's sarcoma, melanoma. interferon-alpha-induced
sarcoidosis reported repeatedly two reports the
literature cases pulmonary sarcoidosis treated interferon-1b therapy: 
one advanced renal cell carcinoma multiple myeloma. a
35-year-old man chronic immune-modulant interferon-1b-based therapy for
multiple sclerosis presented neurology unit mild dyspnoea, dry cough,
and transient pain right upper abdomen. lungs, spleen, liver, almost all
lymphnode stations abdomen mediastinum clearly involved ultrasound
examination, chest x-ray, computed tomography. transbronchial biopsy showed
non-caseating granuloma histopathologic evaluation lungs. best
of knowledge, first report chronic multisystemic sarcoidosis
that associated interferon-beta treatment.

doi: 10.4081/monaldi.2012.165 
pmid: 22662644  [indexed medline]

